Guardian Pharmacy Services Announces Pricing of Upsized Underwritten Public Offering of Class A Common Stock Guardian Pharmacy Services Announces Pricing of Upsized Underwritten Public Offering of Class A Common Stock Share ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. ("Guardian†) (NYSE: GRDN) today announced the pricing of its upsized underwritten public offering (the "Offering†) of 6,000,000 shares of its Class A common stock at a public offering price of $31.00 per share, of which 4,980 ...

Guardian Pharmacy Services (NYSE:GRDN) FY Conference Summary Company Overview - **Company**: Guardian Pharmacy Services - **Industry**: Healthcare Services, specifically focused on pharmacy services for assisted living facilities Key Points Business Performance and Momentum - Strong momentum exiting Q4 2025, primarily driven by vaccine clinics and acquisitions in the Pacific Northwest [2][3] - Successful management of vaccine clinics post-COVID, optimizing purchasing, reimbursement, and labor [2] - Acquisitions have leveraged synergies in national accounts, purchasing platforms, and revenue cycle management [3] Guidance and Future Outlook - Early guidance raised due to confidence in overcoming IRA headwinds, with strong vaccine clinic performance anticipated to continue into Q4 2026 [4] - Potential upside factors include increased acuity and better-than-expected performance from M&A and startups [5] Impact of IRA (Inflation Reduction Act) - Revenue impact from IRA projected to decrease from approximately $150 million in 2026 to $60-65 million in 2027, with further reductions in 2028 [8] - Company aims to mitigate EBITDA impact and return to normal metrics as the business stabilizes [8] M&A Strategy - M&A pipeline remains robust, with a focus on attractive geographies and operators willing to collaborate with Guardian [16][17] - Both M&A and contiguous startups are pursued concurrently to scale the business [18][19] - Recent acquisitions in Seattle and Oregon are performing ahead of schedule due to strong team capabilities and national account interest [21] Industry Trends and Demographics - Significant demographic trends with the aging population, particularly the baby boomer cohort turning 80, expected to drive demand in assisted living [26] - Anticipation of new building developments as occupancy rates approach levels that necessitate expansion [27] Innovative Programs and Technology - Early-stage pilot programs like falls risk prevention show promising results, utilizing clinical expertise and data analytics [30] - Guardian Shield program tracks clinical interventions and ensures medication regimens align with payors' formularies, resulting in cost savings for residents [31][32] - AI is being leveraged to enhance operational efficiency and improve service delivery [33] Financial Health and Capital Deployment - Strong cash conversion ratio of approximately 60%, with no debt on the balance sheet [36] - Future capital deployment strategies include continued M&A, strategic opportunities, and potential share buybacks [36][37] Regulatory Environment - Ongoing focus on drug pricing regulations, with efforts to align reimbursement algorithms with dispensing rates [39] - Participation in the Omnicare bankruptcy process presents potential opportunities for Guardian [40] Conclusion - Guardian Pharmacy Services is positioned for growth with a strong operational foundation, strategic M&A activities, and a favorable demographic trend in the assisted living sector. The company is actively managing regulatory challenges while innovating through technology and clinical programs to enhance service delivery and operational efficiency.

Core Viewpoint - Guardian Pharmacy Services Inc. has shown strong financial performance and has received positive ratings from analysts, indicating a favorable outlook for the company in the long-term care pharmacy services sector [1][5]. Financial Performance - The company reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.27, representing a 54.81% increase from $0.24 per share in the same quarter last year [2]. - Revenues for the quarter ending December 2025 reached $397.62 million, surpassing the Zacks Consensus Estimate by 2.41%, and marking a significant increase from $338.57 million in the same period the previous year [3]. - The net income for the fourth quarter surged by 81% to $21.3 million, compared to $11.8 million in the same period the previous year, while adjusted EBITDA increased by 53% to $39.5 million [4]. - For the full year 2025, Guardian Pharmacy Services reported revenue of $1.45 billion, reflecting an 18% increase from the previous year [4]. Analyst Ratings - Raymond James upgraded Guardian Pharmacy Services to "Outperform" with a price target increase to $40, while the stock was priced at $33.27 at the time of the update [1]. - The company has been assigned a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings prospects driven by an upward trend in earnings estimates [5].

分组1 - Guardian Pharmacy Services reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, and up from $0.24 per share a year ago [1] - The company achieved a revenue of $397.62 million for the quarter, surpassing the Zacks Consensus Estimate by 2.41%, compared to $338.57 million in the same quarter last year [3] - Over the last four quarters, Guardian Pharmacy has exceeded consensus EPS estimates three times and topped revenue estimates four times [2][3] 分组2 - The stock has increased by approximately 11.8% since the beginning of the year, while the S&P 500 has declined by 0.9% [4] - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $336.07 million, and for the current fiscal year, it is $1.10 on revenues of $1.41 billion [8] - The Medical - Drugs industry, to which Guardian Pharmacy belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [9]

Fred Burke: Thank you, Ashley, and good afternoon, everyone. We appreciate your continued interest as we review another very strong quarter and year for Guardian Pharmacy Services, Inc. Turning briefly to the fourth quarter, we delivered results that exceeded our expectations across the board, reflecting solid execution throughout the organization. David will walk through the quarterly details in more depth. What I would like to focus on today is our full-year 2025 performance, including our key financial r ...

Core Insights - Guardian Pharmacy Services reported strong financial performance for 2025, with adjusted EBITDA increasing by 27% year over year and margins expanding to 7.9% despite challenges from acquisitions and market conditions [1][5][10] - The company achieved organic revenue growth of 13%, attributed to new resident additions and increased script volumes, with total reported revenue growth of 18% for the year [2][5] - Management raised the 2026 adjusted EBITDA guidance to $120–$124 million while maintaining revenue guidance of $1.40–$1.42 billion, anticipating to offset pricing impacts from the Inflation Reduction Act [3][5][15] Financial Performance - Adjusted EBITDA for 2025 was reported at $115 million, with a significant increase in Q4 adjusted EBITDA by 53% to $39.5 million [5][10] - The company’s cash balance rose to approximately $66 million, up from $36 million at the end of Q3 2025, indicating strong cash flow generation [11] - Gross profit for Q4 increased by 27% to $85.5 million, with gross margin expanding to 21.5% from 19.8% a year earlier [6][10] Operational Highlights - Guardian served over 205,000 residents, marking a 10% increase year over year, with Q4 script volumes growing by 14% [4][6] - The company completed four acquisitions and continued investments in greenfield startups, funded by strong cash flow [4][11][12] - Vaccine clinics administered over 120,000 vaccines in Q3 and Q4, contributing to improved profitability and operational metrics [7][10] Strategic Outlook - Management noted the operational complexity due to the implementation of the Inflation Reduction Act and its potential impact on pricing and reimbursement dynamics [13][14] - The company is actively monitoring industry conditions, including facility-level consolidation and demographic trends, to identify market opportunities [14] - Future revenue impacts from additional branded drug negotiations under the IRA are expected to be smaller than those anticipated for 2026, with an estimated $65 million revenue headwind in 2027 [17]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth of 12% [19] - Adjusted EBITDA grew 53% year-over-year to $39.5 million, with margins expanding to 9.9% [22] - Full-year 2025 adjusted EBITDA was $115 million, exceeding previous guidance [25] - The company increased its cash balance to $66 million, up from $36 million in Q3 2025 [22] Business Line Data and Key Metrics Changes - The company served over 205,000 residents, a 10% increase year-over-year [19] - Script volume grew 14% year-over-year, with vaccine script volumes up 3% [19][20] - Gross profit rose 27% to $85.5 million, with gross margins expanding to 21.5% from 19.8% [19] Market Data and Key Metrics Changes - The company anticipates a revenue forecast of $1.4 billion to $1.42 billion for 2026, reflecting new pricing impacts from the IRA [26] - The long-term care pharmacy environment is evolving with ongoing consolidation and increasing operational complexity [13] Company Strategy and Development Direction - The company plans to continue investing in acquisitions and greenfield startups while enhancing data analytics capabilities [8] - The company aims to offset anticipated EBITDA impacts from the IRA and maintain service levels during industry transitions [12][11] - The focus remains on supporting partners with reliable execution amid industry changes [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth momentum despite industry challenges, raising 2026 adjusted EBITDA guidance to $120 million-$124 million [17][26] - The demographic shift with the aging population is expected to create incremental tailwinds for the company [13] - Management is closely monitoring the operational complexities introduced by the IRA [11] Other Important Information - The company completed three acquisitions mid-year, contributing to reported revenue growth of 18% for the full year [6] - The company achieved a full-year return on equity of 27% [8] Q&A Session Summary Question: Can you help us understand the durable aspects of Q4 results? - Management indicated that the run rate for EBITDA is approximately $110 million, with variability in Q4 not projected to continue [32] Question: Did the vaccine program contribute more this year than last year? - Management confirmed that the vaccine program continued to be significant in Q4, with improved profitability [34] Question: What progress has been made in balancing profit contributions between generics and branded drugs? - Management noted progress in aligning gross margin dollars with the high volume of generic prescriptions [36] Question: Is the gap between potential margin and realized margin still the same? - Management indicated that the gap has increased to approximately 90 basis points [37] Question: Can you discuss opportunities arising from competitors facing challenges? - Management acknowledged potential opportunities from competitors in distress, particularly in the context of ongoing bankruptcy processes [48] Question: Are you seeing efficiencies in labor costs? - Management stated that efficiencies are primarily due to scaling the existing platform rather than improvements in labor inflation [49] Question: How is the integration of recently acquired facilities progressing? - Management reported faster ramp-up and integration of recently acquired facilities, particularly in the Pacific Northwest [56] Question: What is the outlook for M&A opportunities given the current market conditions? - Management expressed a robust pipeline for M&A in 2026, while remaining disciplined in their approach [60]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth of 12% [15] - Adjusted EBITDA grew 53% year-over-year to $39.5 million, with margins expanding to 9.9% [18] - Full-year adjusted EBITDA for 2025 was $115 million, exceeding guidance [20] Business Line Data and Key Metrics Changes - The company served over 205,000 residents, a 10% increase year-over-year, with script volume growing 14% [15] - Vaccine script volumes increased by 3% year-over-year, contributing to improved profitability due to better purchasing and reimbursement [16] - Adjusted SG&A was 13% of revenue, down from 13.7% in the previous year, reflecting increased scale efficiencies [17] Market Data and Key Metrics Changes - The company anticipates continued pressure in the long-term care pharmacy ecosystem due to the IRA, but believes its scale and local service model will provide stability [10] - The demographic shift, with the first cohort of the "silver tsunami" entering their 80s, is expected to create a tailwind for the company [10] Company Strategy and Development Direction - The company plans to continue investing in acquisitions and greenfield startups while enhancing data analytics capabilities [6] - The focus remains on supporting partners with consistent, reliable execution amid industry changes [11] - The company is raising its 2026 adjusted EBITDA guidance to $120 million-$124 million, reflecting confidence in continued growth momentum [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in offsetting anticipated EBITDA impacts from the IRA in 2026 [9] - The company is closely monitoring operational complexities introduced by the IRA and aims to avoid disruptions to service levels and cash flow [10] - Management highlighted the importance of maintaining service continuity amid industry consolidation and operational changes [48] Other Important Information - The company increased its cash balance by approximately $60 million, reflecting strong cash generation [6] - Full-year return on equity was 27%, underscoring a disciplined approach to capital allocation [7] Q&A Session Summary Question: Can you help us understand what's durable, what's vaccine, and what's non-recurring in the quarter? - Management indicated that the run rate for adjusted EBITDA is approximately $110 million, with certain positive variabilities not projected to continue [25] Question: Did the vaccine program contribute more this year than last year? - Management confirmed that the vaccine program continued to be significant in Q4, with improved reimbursement contributing to profitability [27] Question: What were you able to get done from a contracting standpoint to better balance profit streams? - Management noted progress in aligning gross margin dollars with the high percentage of generic prescriptions dispensed [29] Question: Is the gap between potential margin and realized margin still what it was a couple of quarters ago? - Management reported that the gap has increased to approximately 90 basis points, reflecting ongoing investments for future profitability [30] Question: Can you discuss the opportunity around share gain with struggling competitors? - Management acknowledged potential opportunities arising from industry disruptions, including bankruptcy filings among competitors [41] Question: Are you seeing efficiencies and improvements in labor inflation? - Management indicated that efficiencies are primarily driven by scaling the existing labor force rather than improvements in labor inflation [42] Question: How do you ensure continuity of service amid operational changes? - Management emphasized that industry consolidation provides opportunities to maintain service and meet new operating groups [48]

Financial Data and Key Metrics Changes - For Q4 2025, revenue increased by 17% year-over-year to $397.6 million, with organic growth at 12% [15] - Adjusted EBITDA grew 53% year-over-year to $39.5 million, with margins expanding to 9.9% [18] - Full-year adjusted EBITDA for 2025 was $115 million, exceeding guidance of $104 million-$106 million [20] - The company increased its cash balance to $66 million, up from $36 million in the previous quarter [18] Business Line Data and Key Metrics Changes - The company served over 205,000 residents, a 10% increase year-over-year [15] - Script volume grew by 14% year-over-year, with vaccine script volumes up 3% [15][16] - Gross profit rose 27% to $85.5 million, with gross margins expanding to 21.5% from 19.8% [15] Market Data and Key Metrics Changes - The company anticipates a revenue forecast of $1.4 billion-$1.42 billion for 2026, reflecting new pricing from the IRA [13][21] - The long-term care pharmacy environment is evolving with ongoing consolidation and increasing operational complexity [10] Company Strategy and Development Direction - The company plans to offset anticipated EBITDA impacts from the IRA in 2026 and is focused on maintaining service levels and cash flow [9][10] - The company is actively engaged in discussions for potential acquisitions and greenfield startups to expand its operational footprint [19][53] - The company aims to balance profit contributions between generics and branded drugs, with 92% of prescriptions being generic [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth momentum despite industry changes, with a focus on durable growth and margin expansion [12][13] - The demographic shift with the aging population is expected to create a tailwind for the company [10] - Management acknowledged the challenges posed by the IRA but believes the company's scale and operational discipline will provide stability [10] Other Important Information - The company performed over 100,000 clinical interventions benefiting approximately 74,000 residents, demonstrating its operational and clinical value [6] - The company administered over 120,000 vaccines during the third and fourth quarters, with improved profitability year-over-year [8] Q&A Session Summary Question: Can you help us understand what's durable, what's vaccine, what's non-recurring in the quarter? - Management indicated that the run rate for EBITDA is approximately $110 million, with variability in Q4 not projected to continue [26] Question: Did the vaccine program contribute more this year than last year? - Management confirmed that the vaccine program continued to be significant in Q4, with improved reimbursement and profitability [28] Question: What were you able to get done from a contracting standpoint to better balance the two profit streams? - Management noted progress in aligning gross margin dollars with the high volume of generic prescriptions [30] Question: Is the gap between potential margin and realized margin still what it was a couple of quarters ago? - Management indicated that the gap has increased to approximately 90 basis points, reflecting investments for future profitability [31] Question: Can you discuss the opportunity around share gain with struggling competitors? - Management acknowledged potential opportunities arising from competitors facing challenges, particularly in the context of bankruptcy [42] Question: Are you seeing efficiencies and improvements in labor inflation? - Management clarified that efficiencies are primarily due to scaling the existing platform rather than improvements in labor inflation [43]

Financial Performance - Revenues increased from $1,228,409 in 2024 to $1,448,685 in 2025, representing a growth of approximately 17.9%[407] - Gross profit rose from $244,371 in 2024 to $292,718 in 2025, an increase of about 19.7%[407] - Operating income shifted from a loss of $62,920 in 2024 to a profit of $72,701 in 2025, indicating a significant turnaround[407] - Net income attributable to Guardian Pharmacy Services, Inc. improved from a loss of $110,047 in 2024 to a profit of $49,219 in 2025[407] - Total assets grew from $320,810 in 2024 to $412,658 in 2025, marking an increase of approximately 28.6%[404] - Total liabilities increased from $170,834 in 2024 to $194,734 in 2025, a rise of about 13.9%[404] - Total equity rose from $149,976 in 2024 to $217,924 in 2025, reflecting an increase of approximately 45.2%[404] - Cash and cash equivalents surged from $4,660 in 2024 to $65,619 in 2025, a substantial increase of about 1406.4%[404] - Net income for the year ended December 31, 2024, was a loss of $71,033,000, while for 2025, it is projected to be a profit of $48,958,000[413] - Net cash provided by operating activities increased from $57,960,000 in 2024 to $100,255,000 in 2025, reflecting a growth of 73%[413] Acquisitions and Growth Strategy - The company completed acquisitions of various pharmacy operations for a total purchase price of $16.891 million, resulting in the recognition of intangible assets of $6.586 million related to customer lists[389] - The 2025 acquisitions constituted 7.8% of total assets and 2.7% of revenues for the year ended December 31, 2025[394] - The Company’s growth strategy includes acquiring institutional pharmacies servicing long-term care facilities and other care settings[490] - Total consideration for the 2025 Acquisitions was $16,891, which included $13,725 in cash and $441 in fair value of Class B common stock[492] - The Company issued 24,075 shares of Class B common stock as part of the 2025 Acquisitions, with a fair value determined based on the closing share price of Class A common stock[492] - Contingent earnout payments of up to $2,600 are possible if certain revenue and earnings targets are achieved by acquired entities during the first full four quarters post-acquisition[492] Financial Position and Assets - Cash and cash equivalents at the end of the period increased from $4,660,000 in 2024 to $65,619,000 in 2025, representing a growth of 1,407%[413] - The fair value of contingent consideration obligations increased from $2,700,000 in 2024 to $3,220,000 in 2025, reflecting a rise of 19%[431] - The total preliminary purchase consideration for the 2025 Acquisitions was $16,891[492] - The total purchase consideration for the 2024 Acquisitions was $17,410, which included cash of $14,710 and contingent earnout payments of up to $2,700[501][505] - Goodwill related to the 2024 Acquisitions was recorded at $13,250, with $9,957 expected to be deductible for tax purposes[506] - As of December 31, 2025, total property and equipment increased to $143,367 from $127,863 in 2024, with accumulated depreciation rising to $87,845[509] - The carrying amount of intangible assets increased from $14,912 in 2024 to $18,475 in 2025, with amortization expenses of $3,658 for the latter year[512][513] Expenses and Cost Management - Selling, general, and administrative expenses decreased from $307,291 in 2024 to $220,017 in 2025, a reduction of approximately 28.4%[407] - The company reported a significant decrease in share-based compensation expense from $131,490,000 in 2024 to $13,850,000 in 2025, a reduction of approximately 89%[413] - Delivery expenses increased from $40,716 thousand in 2024 to $47,334 thousand in 2025, indicating a rise in costs associated with product delivery[463] - Advertising and marketing expenses rose from $3,502 thousand in 2024 to $3,895 thousand in 2025, reflecting increased investment in promotional activities[464] Taxation and Compliance - The Company is subject to federal and state corporate income taxes following its Corporate Reorganization[478] - The Company prepares tax returns based on interpretations of tax laws, which are subject to examination by taxing authorities[481] - The Company accounts for income taxes using the asset and liability method, recognizing current tax liabilities and deferred tax assets or liabilities[479] - The effective tax rate for the Company was 33.3% in 2025, compared to (6.9)% in 2024, primarily due to share-based compensation charges[562][563] - The Company had no uncertain tax positions as of December 31, 2025, indicating a stable tax compliance status[567] Internal Controls and Risk Management - The company’s internal control over financial reporting was deemed effective as of December 31, 2025, based on the COSO criteria[393] - The company’s management is responsible for maintaining effective internal control over financial reporting, which includes assessing the effectiveness of these controls[396] - The company faces risks related to government efforts to lower pharmaceutical costs, which could impact its financial performance[11] - The company is exposed to market risks, primarily interest rate sensitivities, which have not significantly impacted its financial condition historically[379] Stock and Shareholder Information - The market price of the company's Class A common stock has experienced substantial volatility due to lower trading volumes and a limited public float[14] - The weighted-average Class A and Class B common shares outstanding increased from 62,005,811 in 2024 to 62,386,253 in 2025[407] - The company had no anti-dilutive shares for the year ended December 31, 2025, while there were 99,892 and 576,113 anti-dilutive unvested Restricted Stock Units for Class A and B common stock, respectively, for the year ended December 31, 2024[536] - The company’s weighted average shares of Class A and Class B common stock outstanding used to calculate diluted net income per share were 23,276,354 for Class A and 40,020,769 for Class B for the year ended December 31, 2025[535] Legal and Regulatory Matters - The company recorded legal expenses of $5,084,000 and $6,333,000 for the years ended December 31, 2024 and 2025, respectively[528] - The company performed its annual goodwill impairment assessment on October 1, 2025, and no impairment was recognized[510]